Africa access: moving fast, outcome uncertain.
In many developing countries fewer than one in a thousand persons with HIV receive modern treatment, mainly because they cannot pay for the drugs, which are often sold at rich-country prices although they cost little to manufacture. Affordable treatments are clearly possible, but have been held back for years due to pharmaceutical companies' fears over patent protection. Now there is intense interest in finding solutions, and several possible approaches are on the table.